1.Population-Based Incidence Rates of Subarachnoid Hemorrhage in Japan: The Shiga Stroke and Heart Attack Registry
Satoshi SHITARA ; Sachiko TANAKA-MIZUNO ; Naoyuki TAKASHIMA ; Takako FUJII ; Hisatomi ARIMA ; Yoshikuni KITA ; Atsushi TSUJI ; Akihiro KITAMURA ; Makoto URUSHITANI ; Katsuyuki MIURA ; Kazuhiko NOZAKI ;
Journal of Stroke 2022;24(2):292-295
2.Long-Term Survival after Stroke in 1.4 Million Japanese Population: Shiga Stroke and Heart Attack Registry
Naoyuki TAKASHIMA ; Hisatomi ARIMA ; Yoshikuni KITA ; Takako FUJII ; Sachiko TANAKA-MIZUNO ; Satoshi SHITARA ; Akihiro KITAMURA ; Yoshihisa SUGIMOTO ; Makoto URUSHITANI ; Katsuyuki MIURA ; Kazuhiko NOZAKI
Journal of Stroke 2020;22(3):336-344
Background:
and Purpose Although numerous measures for stroke exist, stroke remains one of the leading causes of death in Japan. In this study, we aimed to determine the long-term survival rate after first-ever stroke using data from a large-scale population-based stroke registry study in Japan.
Methods:
Part of the Shiga Stroke and Heart Attack Registry, the Shiga Stroke Registry is an ongoing population-based registry study of stroke, which covers approximately 1.4 million residents of Shiga Prefecture in Japan. A total 1,880 patients with non-fatal first-ever stroke (among 29-day survivors after stroke onset) registered in 2011 were followed up until December 2016. Five-year cumulative survival rates were estimated using the Kaplan-Meier method, according to subtype of the index stroke. Cox proportional hazards models were used to assess predictors of subsequent all-cause death.
Results:
During an average 4.3-year follow-up period, 677 patients died. The 5-year cumulative survival rate after non-fatal first-ever stroke was 65.9%. Heterogeneity was present in 5-year cumulative survival according to stroke subtype: lacunar infarction, 75.1%; large-artery infarction, 61.5%; cardioembolic infarction, 44.9%; intracerebral hemorrhage, 69.1%; and subarachnoid hemorrhage, 77.9%. Age, male sex, Japan Coma Scale score on admission, and modified Rankin Scale score before stroke onset were associated with increased mortality during the chronic phase of ischemic and hemorrhagic stroke.
Conclusions
In this study conducted in a real-world setting of Japan, the 5-year survival rate after non-fatal first-ever stroke remained low, particularly among patients with cardioembolic infarction and large-artery infarction in the present population-based stroke registry.
3.Efficacy of Novel Ultrathin Single-Balloon Enteroscopy for Crohn’s Disease:A Propensity Score-Matched Study
Kaoru TAKABAYASHI ; Naoki HOSOE ; Motohiko KATO ; Yukie HAYASH ; Ryoichi MIYANAGA ; Kosaku NANKI ; Kayoko FUKUHARA ; Yohei Mikami SHINTA MIZUNO ; Tomohisa SUJINO ; Makoto MUTAGUCHI ; Makoto NAGANUMA ; Naohisa YAHAGI ; Haruhiko OGATA ; Takanori KANAI ; Shinta MIZUNO
Gut and Liver 2020;14(5):619-625
Background/Aims:
The evaluation of small bowel lesions of Crohn’s disease (CD) using balloon-assisted enteroscopy (BAE) is crucial because mucosal healing is associated with a good prognosis. However, BAE procedures are invasive, requiring sedation or analgesia to reduce the patient’s pain.This study evaluated the clinical usefulness of a novel ul-trathin single-balloon enteroscopy (SBE) procedure for CD.
Methods:
This single-center retrospective study included 102 CD patients who underwent trans-anal SBE between Janu-ary 2012 and May 2018. Of these patients, 82 underwent enteroscopy using conventional SBE, while 20 underwent ultrathin SBE. Patients were analyzed using propensity score matching, with 20 patients per group. The median duration of the examination, terminal ileum intubation rate, median cecum intubation time, median insertion depth, adverse events, and sedated dose in each group were compared.
Results:
Before propensity score matching, the conventional SBE group had a larger number of surgical history patients than the ultrathin SBE group (p=0.05). After matching, the two groups did not significantly differ clinically. There were no significant differences in the mean duration of the examina-tion, cecum intubation time, or terminal ileal intubation rate between ultrathin SBE and conventional SBE. The mean in-sertion depth of ultrathin SBE tended to be deeper than that of conventional SBE (p=0.09). The use of ultrathin SBE also reduced the sedative dose during needed for enteroscopy compared with conventional SBE (p=0.005).
Conclusions
Novel ultrathin SBE may be less painful for CD patients than conventional SBE.
4.5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis
Shinta MIZUNO ; Keiko ONO ; Yohei MIKAMI ; Makoto NAGANUMA ; Tomohiro FUKUDA ; Kazuhiro MINAMI ; Tatsuhiro MASAOKA ; Soichiro TERADA ; Takeshi YOSHIDA ; Keiichiro SAIGUSA ; Norimichi HIRAHARA ; Hiroaki MIYATA ; Wataru SUDA ; Masahira HATTORI ; Takanori KANAI
Intestinal Research 2020;18(1):69-78
Background/Aims:
5-Aminosalicylic acid (ASA) causes intolerance reactions in some patients. This study was performed to examine the prognosis of patients with ulcerative colitis (UC) and 5-ASA intolerance, and to evaluate the potential interaction between 5-ASA intolerance and the intestinal microbiota.
Methods:
We performed a retrospective cohort study of patients with UC who visited participating hospitals. The primary endpoint was to compare the incidence of hospitalization within 12 months between the 5-ASA intolerance group and the 5-ASA tolerance group. The secondary endpoint was to compare the risk of adverse clinical outcomes after the start of biologics between the 2 groups. We also assessed the correlation between 5-ASA intolerance and microbial change in an independently recruited cohort of patients with UC.
Results:
Of 793 patients, 59 (7.4%) were assigned to the 5-ASA intolerance group and 734 (92.5%) were assigned to the 5-ASA tolerance group. The admission rate and incidence of corticosteroid use were significantly higher in the intolerance than tolerance group (P< 0.001). In 108 patients undergoing treatment with anti-tumor necrosis factor biologics, 5-ASA intolerance increased the incidence of additional induction therapy after starting biologics (P< 0.001). The 5-ASA intolerance group had a greater abundance of bacteria in the genera Faecalibacterium, Streptococcus, and Clostridium than the 5-ASA tolerance group (P< 0.05).
Conclusions
In patients with UC, 5-ASA intolerance is associated with a risk of adverse clinical outcomes and dysbiosis. Bacterial therapeutic optimization of 5-ASA administration may be important for improving the prognosis of patients with UC.
5.Effect of the Hot Water Extract of Coix lacryma-jobi L. var. ma-yuen Stapf with Husks on Skin Improvement
Shizuka UEHARA ; Chikako YOSHIKAWA ; Mitsuru YOSHIDA ; Makoto MIZUNO ; Akemi RYU ; Hoko KYO ; Nobutaka SUZUKI
Japanese Journal of Complementary and Alternative Medicine 2019;16(1):33-38
We examined the influence of hot water extract of coix seed (Coix lacryma-jobi L. var. ma-yuen Stapf) with husks on facial skin. Ten females (28-58 years old) took hot water extract of coix seed with husks 1 g/day for 8 weeks, and various skin parameters were measured. The results showed that the total amount of subsurface reflection of blue light, which is an index of skin translucency, increased significantly after 8 weeks of intake (p = 0.011). In addition, skin texture improved significantly after 4 and 8 weeks of intake (p = 0.007, p = 0.042). Additionally, the condition of tape-stripped stratum corneum also indicated significant improvement after 4 and 8 weeks intake (p = 0.0002, p = 0.020). These results suggested that the hot water extract of coix seed with husks exhibited effects even at 1 g/day, which is less than in previous reports.
6.Infectious peritonitis after endoscopic ultrasound-guided biliary drainage in a patient with ascites
Nozomi OKUNO ; Kazuo HARA ; Nobumasa MIZUNO ; Takamichi KUWAHARA ; Hiromichi IWAYA ; Masahiro TAJIKA ; Tsutomu TANAKA ; Makoto ISHIHARA ; Yutaka HIRAYAMA ; Sachiyo ONISHI ; Kazuhiro TORIYAMA ; Ayako ITO ; Naosuke KURAOKA ; Shimpei MATSUMOTO ; Masahiro OBATA ; Muneji YASUDA ; Yusuke KURITA ; Hiroki TANAKA ; Yasumasa NIWA
Gastrointestinal Intervention 2018;7(1):40-43
SUMMARY OF EVENT: Bacterial, mycotic peritonitis and Candida fungemia developed in a patient with moderate ascites who had undergone endoscopic ultrasound-guided biliary drainage (EUS-BD). Antibiotics and antifungal agent were administered and ascites drainage was performed. Although the infection improved, the patient's general condition gradually deteriorated due to aggravation of the primary cancer and he died. TEACHING POINT: This is the first report to describe infectious peritonitis after EUS-BD. Ascites carries the potential risk of severe complications. As such, in patients with ascites, endoscopic retrograde cholangiopancreatography (ERCP) is typically preferred over EUS-BD or percutaneous drainage to prevent bile leakage. However, ERCP may not be possible in some patients with tumor invasion of the duodenum or with surgically altered anatomy. Thus, in patients with ascites who require EUS-BD, we recommend inserting the drainage tube percutaneously and draining the ascites before and after the intervention in order to prevent severe infection.
Anti-Bacterial Agents
;
Ascites
;
Bile
;
Candida
;
Cholangiopancreatography, Endoscopic Retrograde
;
Drainage
;
Duodenum
;
Endosonography
;
Fungemia
;
Humans
;
Peritonitis
7.Fecal microbiota transplantation for recurrent Clostridium difficile infection in a patient with ulcerative colitis
Kosaku NANKI ; Shinta MIZUNO ; Katsuyoshi MATSUOKA ; Keiko ONO ; Shinya SUGIMOTO ; Hiroki KIYOHARA ; Mari ARAI ; Moeko NAKASHIMA ; Kozue TAKESHITA ; Keiichiro SAIGUSA ; Mitsutoshi SENOH ; Tadashi FUKUDA ; Makoto NAGANUMA ; Haru KATO ; Wataru SUDA ; Masahira HATTORI ; Takanori KANAI
Intestinal Research 2018;16(1):142-146
Fecal microbiota transplantation (FMT) has been reported as a safe and effective therapy in patients with refractory and recurrent Clostridium difficile infection (CDI). FMT has also been reported as a promising therapy in patients with ulcerative colitis (UC). Both, CDI and UC, are believed to be caused by dysbiosis, such as altered compositions or decreased diversity of the intestinal microbiota. This report describes a patient with UC in remission with a second recurrent episode of CDI, who was treated with FMT. A single FMT performed via colonoscopy completely resolved the patient's diarrhea and eradicated C. difficile bacteriologically without any severe complications. Molecular biological analysis of the patient's fecal microbiota showed that FMT could dramatically change the altered composition of intestinal microbiota and restore its diversity. Despite the restoration of the intestinal microbiota, FMT could not prevent a relapse of UC in this patient. However, it improved the intestinal symptoms of CDI and could prevent further recurrences of CDI.
Clostridium difficile
;
Clostridium
;
Colitis, Ulcerative
;
Colonoscopy
;
Diarrhea
;
Dysbiosis
;
Fecal Microbiota Transplantation
;
Gastrointestinal Microbiome
;
Humans
;
Microbiota
;
Recurrence
;
Ulcer
8.Exercise Facilitation Based on the Theory of Cognitive Behavioral Therapy for Chronic Musculoskeletal Pain
Shinji KIMURA ; Masako HOSOI ; Takako MATSUBARA ; Masahiko SHIBATA ; Yasuyuki MIZUNO ; Makoto NISHIHARA ; Takanori MURAKAMI ; Naofumi OTSURU
The Japanese Journal of Rehabilitation Medicine 2018;55(3):206-214
9.β-(1,3)-Glucan derived from Candida albicans induces inflammatory cytokines from macrophages and lamina propria mononuclear cells derived from patients with Crohn's disease.
Kiyoto MORI ; Makoto NAGANUMA ; Shinta MIZUNO ; Hiroaki SUZUKI ; Mina T. KITAZUME ; Katsuyoshi SHIMAMURA ; Sayako CHIBA ; Akira SUGITA ; Katsuyoshi MATSUOKA ; Tadakazu HISAMATSU ; Takanori KANAI
Intestinal Research 2018;16(3):384-392
BACKGROUND/AIMS: Recent research has highlighted the importance of interactions between commensal fungi and intestinal inflammation. However, there are few studies investigating whether commensal fungi contribute to inflammation in patients with Crohn's disease (CD). The aim of this study is to investigate reveal interactions between commensal fungi and host immune cells in CD. METHODS: CD14-positive monocytes were isolated from peripheral blood mononuclear cells from healthy human volunteers and then differentiated in the presence of macrophage colony-stimulating factor (M-CSF) (referred to as M-macrophages, M-Mϕs) or M-CSF and interferon-γ (IFN-γ) (referred to as M-gamma macrophages, Mγ-Mϕs). Cytokine production by these in vitro differentiated macrophages in response to β-(1,3)-glucan was analyzed by flow cytometry. Expression of Dectin-1 was examined using flow cytometry, western blotting, and quantitative reverse transcription-polymerase chain reaction. Cytokine production by in vitro differentiated macrophages in response to β-(1,3)-glucan was measured in the presence of an anti-Dectin-1 receptor antagonist, anti-Syr, or an anti-Fas-1 antibody. Cytokine production by lamina propria mononuclear cells (LPMCs) derived from CD patients in response to β-(1,3)-glucan was also analyzed. RESULTS: Mγ-Mϕs produced a large amount of tumor necrosis factor-α (TNF-α) and interleukin-6 in response to β-(1,3)-glucan. Dectin-1 expression was significantly higher in Mγ-Mϕs than in M-Mϕs. The increase in TNF-α production by Mγ-Mϕs stimulated with glucan was reversed by blocking Dectin-1, Syr or Fas-1. LPMCs derived from CD patients stimulated with β-(1,3)-glucan produced significantly higher amount of TNF-α than LPMCs derived from UC patients. CONCLUSIONS: These results suggest that commensal fungal microbiota may contribute to the pathogenesis of CD by inducing macrophages-derived pro-inflammatory cytokines.
Blotting, Western
;
Candida albicans*
;
Candida*
;
Crohn Disease*
;
Cytokines*
;
Flow Cytometry
;
Fungi
;
Healthy Volunteers
;
Humans
;
In Vitro Techniques
;
Inflammation
;
Interleukin-6
;
Macrophage Colony-Stimulating Factor
;
Macrophages*
;
Microbiota
;
Monocytes
;
Mucous Membrane*
;
Necrosis
;
Tumor Necrosis Factor-alpha
10.Single fecal microbiota transplantation failed to change intestinal microbiota and had limited effectiveness against ulcerative colitis in Japanese patients.
Shinta MIZUNO ; Kosaku NANKI ; Katsuyoshi MATSUOKA ; Keiichiro SAIGUSA ; Keiko ONO ; Mari ARAI ; Shinya SUGIMOTO ; Hiroki KIYOHARA ; Moeko NAKASHIMA ; Kozue TAKESHITA ; Makoto NAGANUMA ; Wataru SUDA ; Masahira HATTORI ; Takanori KANAI
Intestinal Research 2017;15(1):68-74
BACKGROUND/AIMS: Recent developments in analytical techniques including next-generation sequencing have clarified the correlation between intestinal microbiota and inflammatory bowel disease. Fecal microbiota transplantation (FMT) for patients with ulcerative colitis (UC) is proposed as a potential approach to resolving their dysbiosis; however, its safety and efficacy have not been confirmed. This single-arm, open-label, non-randomized study aimed to evaluate the safety and efficacy of FMT for Japanese patients with UC as the first registered clinical trial in Japan. METHODS: We enrolled 10 patients with active UC despite medical therapy. The donors were the patients' relatives and were carefully screened for infectious diseases. Fecal material was administered via colonoscopy, and the primary endpoint was the presence or absence of serious adverse events related to FMT. The secondary endpoint was a change in partial Mayo score at 12 weeks post-FMT. Scores ≤2 were considered a clinical response. Fecal samples were collected to follow changes in gut microbiota, while extracted complementary DNA were analyzed by a next-generation sequencer. We obtained written informed consent from all patients and donors. This study was approved by our Institutional Review Board and is registered in the University hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN 000012814). RESULTS: Five patients with moderate disease and five with severe disease were enrolled. No severe adverse effects were observed. One patient achieved clinical response; however, none of the patients' microbiota diversity recovered to the donor levels. CONCLUSIONS: The use of single FMT for UC was safe; however, we failed to show its clinical efficacy and potential to change the intestinal microbiota.
Asian Continental Ancestry Group*
;
Colitis, Ulcerative*
;
Colonoscopy
;
Communicable Diseases
;
DNA, Complementary
;
Dysbiosis
;
Ethics Committees, Research
;
Fecal Microbiota Transplantation*
;
Gastrointestinal Microbiome*
;
Humans
;
Inflammatory Bowel Diseases
;
Information Services
;
Informed Consent
;
Japan
;
Microbiota
;
Tissue Donors
;
Treatment Outcome
;
Ulcer*


Result Analysis
Print
Save
E-mail